Loading clinical trials...
Loading clinical trials...
To Compare the Efficacy and Safety of Oral SHR7280 Tablets With Ganirelix Acetate Injection in Female Subjects With Infertility Receiving Controlled Ovarian Hyperstimulation Therapy: A Multi-center, Randomized, Parallel-Group, Double-Blind, Dual-Simulation, Non-Inferiority Phase III Clinical Study
Conditions
Interventions
SHR7280；Ganirelix Acetate Injection simulant
SHR7280 simulant； Ganirelix Acetate Injection
Locations
1
China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Start Date
August 29, 2023
Primary Completion Date
May 2, 2025
Completion Date
May 2, 2025
Last Updated
September 15, 2025
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions